which are cold-induced and exercise-induced myotonia, is an autosomal-dominant muscle disease which is classified into one of a group of muscle diseases, so-called muscle "sodium channelopathies" caused by missense mutations in the gene coding for the skeletal muscle sodium channel a-subunit (SCN4A) (1) (2) (3) (4) . Such muscle sodium channelopathies share a commonabnormality of muscle membraneexcitability, which could be expressed as myotonia or weakness. These channelopathies include three allelic disorders, namely paramyotonia congenita, hyperkalemic periodic paralysis and sodium channel myotonias (1-3, 5).
These mutations of the skeletal muscle sodium channel causing sodium channelopathies all exhibit gain-of-function defects. The pathophysiology of sodium channelopathies is currently considered as follows. In the sodium channelopathies of skeletal muscle, the mutant sodiumchannels pass more Na+ current through the muscle membranethan normal, mostly due to an impairment of fast inactivation of the mutant sodium channels, resulting in either slight depolarization with hyperexcitability (myotonia) or sustained depolarization with inexcitability (paresis) (1, 2, 4, 5) . In regard to paramyotonia congenita, the mutant sodium channels mostly show abnormalities of channel gating with a slowing of the rate of fast inactivation and with an acceleration of the rate of recovery from inactivation (1, 2, 4, 5), whereby they spend less time in the inactivated state, resulting in a persistent inward Na+current that promotes excessive membranedepolarization and abnormal trains of myotonic potentials (6) . SCN4Acontains four repeated domains, designated Dl- See also p 856.
This mutation detected in their patients was described first by McClatchey et al (8) , and since then it has been reported exclusively in paramyotonia congenita. The expression of muscle sodium channelopathies depends on the structure and polarity of substituted amino acids at a mutation site, which may partly play a role in phenotypic variability. In addition, there may be other factors influencing disease expression, including genetic polymorphisms elsewhere, effects of other types of muscle ion channels, and so on (1). It is extremely important to diagnose muscle sodium channelopathies by clinical findings and DNAanalysis, not only for treatment but also for prevention of complications during anesthesia and surgery, which load special risks for patients with such diseases mostly by precipitating myotonia. If we realize that the patient is suffering from one of the muscle sodium channelopathies, propofol (6), the effects of which would be expected to decrease the membrane hyperexcitability caused by sodium channel mutations, should be selected as an anesthetic agent rather than the use of depolarizing neuromuscular blocking agents such as succinylcholine or thiamylal which both precipitate generalized myotonia. 
